Cadrofloxacin
(Synonyms: 盐酸卡德沙星,Caderofloxacin; CS-940) 目录号 : GC64102
Cadrofloxacin (Caderofloxacin; CS-940) 是一种口服活性氟喹诺酮类药物，对需氧/厌氧革兰氏阳性菌和革兰氏阴性菌有效。Cadrofloxacin可用于感染性疾病的研究。
Cas No.:153808-85-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases[1][2][3].
Cadrofloxacin against M.tuberculosis with a MIC50 of 0.25 μg/mL[1].Cadrofloxacin against Acinetobacter spp. and Stenotrophomonas (Xanthomonas) maltophilia with MIC90s of 0.03 and 2 μg/ml, respectively[2].Cadrofloxacin against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria spp. with MIC90s less than or equal to 0.06 μg/mL[2].Cadrofloxacin against members of the family Enterobacteriaceae with MIC90s of 0.015 to 16 μg/mL (median MIC90, 0.06 μg/mL)[2].
Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats[2].
[1]. Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58.
[2]. Biedenbach DJ, et al. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30.
[3]. Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58.
| Cas No. | 153808-85-6 | SDF | Download SDF |
| 别名 | 盐酸卡德沙星,Caderofloxacin; CS-940 | ||
| 分子式 | C19H20F3N3O4 | 分子量 | 411.38 |
| 溶解度 | DMSO : 10 mg/mL (24.31 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 80°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4308 mL | 12.1542 mL | 24.3084 mL |
| 5 mM | 0.4862 mL | 2.4308 mL | 4.8617 mL |
| 10 mM | 0.2431 mL | 1.2154 mL | 2.4308 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Transfer of Cadrofloxacin, a novel fluoroquinolone antibacterial, into the gallbladder tissue and bile]
Jpn J Antibiot 2004 Feb;57(1):118-23.PMID:15116576doi
Clinical pharmacological studies of a novel fluoroquinolone antibacterial drug, Cadrofloxacin, were performed in 12 surgical patients by investigating the transfer of Cadrofloxacin into the gallbladder tissue and bile. They were scheduled for cholecystectomy (n = 6) or had undergone a percutaneous transhepatic biliary drainage (n = 5) or gallbladder drainage (n = 1) at the Second Department of Surgery, Wakayama Medical University. A single dose of Cadrofloxacin was orally administered to all patients at a dose of 200 mg. The results were as follows: 1) Serum and gallbladder tissue levels of Cadrofloxacin after 2.9-5.7 hours were 0.6-2.5 micrograms/ml and 0.6-8.6 micrograms/ml, respectively. The gallbladder/serum ratios of drug concentration were 0.6-3.4. 2) Levels of Cadrofloxacin in bile reached a peak of 2.5-12.9 micrograms/ml after individually different period of time. Cumulative bile recoverlies of Cadrofloxacin (unchanged compound + glucuronide conjugate) within the first 6 hours were 0.02-0.49%, and 0.08-0.75% within 0-12 hours. The mean value of [glucuronide conjugate/unchanged compound] in bile was 37%, although the values depended on the patients.